Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Alexander Kulczycki

Hospitalist Bar Harbor, ME Medical Doctor

NPI 1992932248 CMS profile 317405

10 Wayman Ln, Bar Harbor, ME 04609

Open in the dashboard

General payments

$5,523

400 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Alexander Kulczycki of Bar Harbor, ME is reported in the CMS Open Payments database as having received $5,523 across 400 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $212 14
2022 General $1,073 72
2021 General $1,659 117
2020 General $1,384 101
2019 General $1,196 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Kulczycki
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Alexander Kulczycki were reported at $0. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Alexander Kulczycki Hospitalist median Middle half National median
2019 $1,196 $96 $28–$201 $163
2020 $1,384 $48 $19–$125 $114
2021 $1,659 $70 $23–$167 $132
2022 $1,073 $85 $27–$174 $149
2023 $212 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $0 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $1,126 76 payments
  2. Novo Nordisk Inc $840 63 payments
  3. Pfizer Inc. $581 47 payments
  4. Lilly USA, LLC $506 36 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $375 27 payments
  6. Merck Sharp & Dohme Corporation $313 23 payments
  7. GlaxoSmithKline, LLC. $274 20 payments
  8. Janssen Pharmaceuticals, Inc $228 16 payments
  9. Esperion Therapeutics, Inc. $189 14 payments
  10. Amarin Pharma Inc. $169 12 payments
  11. Other $924 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $5,511 399 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2023
  1. FARXIGA $759 49 payments
  2. Ozempic $489 37 payments
  3. RYBELSUS $474 36 payments
  4. JARDIANCE Diabetes $455 32 payments
  5. ELIQUIS $441 35 payments
  6. JARDIANCE Diabetes $290 21 payments
  7. JANUVIA $283 21 payments
  8. TRULICITY $280 20 payments
  9. STEGLATRO $256 19 payments
  10. BREZTRI $255 10 payments
  11. Other $4,386 321 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

251

Median for Hospitalist: 109

Drug cost

$14,197

Median for Hospitalist: $6,399

Branded share of claims

10.4%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 26 $7,558
Donepezil Hcl Generic 14 $1,884
Methscopolamine Bromide Generic 11 $919
Atorvastatin Calcium Generic 50 $847
Tamsulosin Hcl Generic 28 $729
Losartan Potassium Generic 26 $632
Torsemide Generic 20 $631
Omeprazole Generic 15 $325
Potassium Chloride Generic 17 $292
Spironolactone Generic 16 $196

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$12,918

Medicare's payments for the services billed

Medicare patients

77

Average age 80

Services billed

222

44 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 51%
Chronic kidney disease 51%
Arthritis 44%
Heart failure 43%
Depression 35%
Ischemic heart disease 34%
COPD 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

400 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Maine

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record